Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8147840 | Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, tha... | 04/03/2012 |
| 8119140 | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins The present invention relates to mosaic clade M HIV-1 Nef polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human. ... | 02/21/2012 |
| 8034350 | Methylated tat polypeptides and methods of use thereof The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents th... | 10/11/2011 |
| 8029797 | Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition collectively represents the in vivo variability seen in immunogenic epitopes fro... | 10/04/2011 |
| 8017126 | Modified HIV-1 envelope proteins The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes. ... | 09/13/2011 |
| 7993651 | Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes Disclosed is an immunogen in sterile form suitable for administration to a human subject, the immunogen comprising: at least a portion of the gag protein of HIV, said gag protein being from an HIV clade or having a consensus sequence for one or more HIV clades, and ... | 08/09/2011 |
| 7988974 | Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 o... | 08/02/2011 |
| 7988975 | Modified HIV-1 group M cyclic gp41 peptides and their use in the detection of anti-HIV-1 antibodies The invention involves a synthetic peptide derived from HIV-1 virus gp41 having sequence where X615 is F or G, a method of preparing the synthetic peptide, a composition and a kit containing the synthetic peptide, ... | 08/02/2011 |
| 7951377 | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens The present invention relates to mosaic clade M HIV-1 Env polypeptides and to compositions comprising same. The polypeptides of the invention are suitable for use in inducing an immune response to HIV-1 in a human. ... | 05/31/2011 |
| 7943139 | Methods of generating a humoral immune response against human immunodeficiency virus (HIV) comprising administering Nef apoptotic motif-containing polypeptide-conjugates A small peptide of 10 or 11 mers, when linked to an immunogenic moiety, can protect against naferious effects of Nef protein of HIV. The vaccine is not used to induce sterilizing immunity, but to block the ability of soluble Nef protein to induce apoptosis, and to t... | 05/17/2011 |
| 7943140 | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 A self-adjuvanting immunogenic composition comprising multiple immunogens, each immunogen comprising a lipopeptide cap, a universal T helper sequence and an immunodominant HIV-1 Tat B cell epitope. The immunogen also comprises one or more linker sequences and/or pol... | 05/17/2011 |
| 7919100 | Soluble and stabilized trimeric form of gp41 polypeptides The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: —a size conveni... | 04/05/2011 |
| 7919101 | Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also dis... | 04/05/2011 |
| 7901690 | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV is disclosed. The composition and methods described herein are for the use of a DNA composition that encodes one or more different HIV envelope glycoproteins. The DNA c... | 03/08/2011 |
| 7838001 | Synthetic peptides useful in biological essays for detecting infections caused by group O HIV-1 viruses Synthetic peptides of the monomer type with 13 to 33 amino acids, in linear form or in a form cyclized by means of inter-cysteine disulphide bridges, have the general formula (I): Δ-Z-TrpGlyCys-Θ-CysTyrThrSer-Ω (I) wherein Δ is a biotiny... | 11/23/2010 |
| 7794725 | Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and ho... | 09/14/2010 |
| 7790171 | Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and ... | 09/07/2010 |
| 7744897 | Human immunodeficiency virus gp41 mimetibody polypeptides HIV gp41 mimetibody polypeptides and encoding polynucleotides are disclosed. Methods of utilizing the polypeptides to reduce or inhibit HIV fusion with a cell membrane and entry into target cells are also disclosed. ... | 06/29/2010 |
| 7744896 | HIV-1 Tat compositions The present invention refers to Tat as the active principle for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biolog... | 06/29/2010 |
| 7731971 | Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achi... | 06/08/2010 |
| 7718180 | Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The presen... | 05/18/2010 |
| 7709004 | Method of producing an HIV-1 immune response The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are b... | 05/04/2010 |
| 7709003 | Method of producing an HIV-1 immune response The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are b... | 05/04/2010 |
| 7611712 | Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The presen... | 11/03/2009 |
| 7588764 | Compositions comprising human immunodeficiency virus Tat adsorbed to the surface of anionic nanoparticles Non-denatured, recombinant human immunodeficiency virus (HIV) Tat that is free of bacterial RNA and endotoxin is employed in an anti-HIV vaccine. A process of producing the recombinant Tat protein includes steps for removing bacterial RNA from the recombinant Tat an... | 09/15/2009 |
| 7541036 | Human immunodeficiency virus type 1 (HIV-1) matrix (MA or p17) polypeptide capable of inducing anti-p17 antibodies that neutralize the proinflammatory activities of the MA protein New isolated polypeptides of the protein p17 of HIV are described, represented by the formula: NH2-X1-Gly-X2-X3-Leu-Asp-X4-Trp-Glu-X5-Ile-X6-Leu-Arg-COOH (SEQ ID NO:1) in which X1 | 06/02/2009 |
| 7510715 | Protozoan derived compositions and methods of use thereof The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or... | 03/31/2009 |
| 7488481 | Polypeptides derived from anti-HIV-1 gp120 antibodies that abrogate gp120 binding to CCR5 The present invention is directed to peptides that are capable of blocking the entry of HIV-1 into host cells by means of the CCR5 receptor. The affinity of the peptides for gp120 on the HIV viral surface may be increased by sulfating tyrosine residues. In addition,... | 02/10/2009 |
| 7442525 | Method for expressing HIV polypeptides Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare... | 10/28/2008 |
| 7438914 | Composition and method for enhancing immune response A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptide... | 10/21/2008 |
| 7431928 | Identification of new CD8 epitopes from HIV-1 proteins The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 pro... | 10/07/2008 |
| 7410801 | Lambda phage display system and the process The present invention relates to a process of obtaining recombinant lambdoid bacteriophage with high density display of functional peptides and proteins on surface of said phage comprising of: constructing a donor plasmid having a nucleotide sequence that defines th... | 08/12/2008 |
| 7408053 | Recombinant DNA constructs for GAG polypeptides and polypeptides produced thereby Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare... | 08/05/2008 |
| 7384637 | Drug for AIDS treatment Raising the T-cell count in an HIV positive patient having a low T-cell count by orally administering an effective amount of a composition containing a material obtained by treating whole human blood or white cells obtained from HIV positive patients with cold aqueo... | 06/10/2008 |
| 7384734 | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorith... | 06/10/2008 |
| 7378490 | Cyclic peptides and aids vaccines Cyclic peptides comprising, as a constituent chain or chains, one or two amino acid sequences selected from the groups consisting of the amino acid sequence Glu-Ala-Asp-Asp-Arg and the amino acid sequence Ser-Gln-Lys-Glu-Gly, and AIDS vaccines containing the cyclic ... | 05/27/2008 |
| 7378515 | Synthetic gagpol genes and their uses The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and v... | 05/27/2008 |
| 7364744 | Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and... | 04/29/2008 |
| 7361459 | Antiviral inhibition of capsid proteins Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a compound that binds to the apica... | 04/22/2008 |
| 7351412 | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus (HIV). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associat... | 04/01/2008 |
